{"id":13024,"date":"2010-03-23T10:30:00","date_gmt":"2010-03-23T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutica-il-futuro-e-delle-medie-imprese\/"},"modified":"2010-03-23T10:30:00","modified_gmt":"2010-03-23T09:30:00","slug":"farmaceutica-il-futuro-e-delle-medie-imprese","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutica-il-futuro-e-delle-medie-imprese\/","title":{"rendered":"Pharmaceuticals: the future belongs to medium-sized enterprises"},"content":{"rendered":"<p><img decoding=\"async\" style=\"width: 100px\" id=\"DLImmagini__ctl66_Img\" border=\"0\" alt=\"\" src=\"http:\/\/www.informatori.aiisf.it\/img\/Archivio\/\/N2967.jpg\" width=\"100\" \/>Made in Italy pharmaceuticals will be able to be competitive if they reach 2 billion euros in turnover and are able to concentrate on individual therapeutic areas and operate with a global reach. This was reported by a study by Enter, the Bocconi Entrepreneurship Research Center, carried out with the contribution of Farmindustria, which examined 11 groups with Italian capital. In favor of medium-sized companies, the expiry in a few years of drug patents that generate 137 billion dollars in annual turnover and the loss of approximately 50% of the value of sales. However, the weak point of the sector concerns the inadequacy of tax incentives for R&amp;D, which are increasingly decisive also in the localization strategy of investments by multinationals. Sergio Domp\u00e8, President of Farmindustria, reiterates: &quot;let&#039;s not miss out on excellence&quot;.<\/p>\n<p>la Repubblica Affari &amp; Finanza Pag.12 \u2013 22\/03\/2010&nbsp; <img decoding=\"async\" style=\"width: 100px\" id=\"DLImmagini__ctl0_Img\" border=\"0\" alt=\"\" src=\"http:\/\/www.informatori.aiisf.it\/img\/Archivio\/\/Copia1_N3512.jpg\" width=\"100\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Le farmaceutiche made in Italy potranno essere competitive se raggiungeranno 2 mld di euro di fatturato e sapranno concentrarsi su singole aree terapeutiche e operare con un raggio d&#8217;azione globale. Lo segnala uno studio di Enter, il Centro di ricerca imprenditorialit&agrave; della Bocconi, realizzato con il contributo di Farmindustria, che ha preso in esame 11 &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13024","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13024"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13024\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}